Skip to main content
xMedica

Search

43 studies match these filters. Showing 1–25 of 43 studies

Search results
Registration numberStudyStatusPhaseEnrolmentSites / countriesStart yearLast updatedActions
NCT07685808Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed i…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 22 sites in total

RecruitingPhase 2360target22 / 12026Nov 18, 2026
NCT07784725A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

✓ Contact✗ Claimed

Nearest site: El Dorado, Kansas, United States — 85 km away · 220 sites in total

RecruitingPhase 32,500target220 / 162026Oct 30, 2026
NCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 230 sites in total

RecruitingPhase 31,500target230 / 162026Oct 28, 2026
NCT07667803A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 325 sites in total

RecruitingPhase 34,500target325 / 192026Oct 13, 2026
NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 92 sites in total

RecruitingPhase 33,200target92 / 52026Oct 5, 2026
NCT07684144Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 45 sites in total

RecruitingPhase 3950target45 / 52026Oct 5, 2026
NCT07817251Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 40 sites in total

RecruitingPhase 3210target40 / 12026Sep 30, 2026
NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith…

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 303 sites in total

RecruitingPhase 32,500target303 / 192026Sep 30, 2026
NCT07619131A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment…

✓ Contact✗ Claimed

Nearest site: Derby, Kansas, United States — 54 km away · 152 sites in total

RecruitingPhase 3600target152 / 112026Sep 10, 2026
NCT07662044A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos…

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 149 sites in total

RecruitingPhase 3800target149 / 132026Aug 31, 2026
NCT07654374A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 74 sites in total · contact listed

RecruitingPhase 31,100target74 / 12026Oct 20, 2026
NCT07606066A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

✓ Contact✗ Claimed

Nearest site: El Dorado, Kansas, United States — 85 km away · 76 sites in total

Recruiting2,150target76 / 72026Aug 25, 2026
NCT07282743Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, on…

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 21 sites in total

RecruitingPhase 2285target21 / 22026Mar 18, 2026
NCT07546929HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel…

✓ Contact✗ Claimed

Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed

RecruitingPhase 2300target25 / 12023Apr 23, 2026
NCT07296484Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed

RecruitingPhase 21,500target61 / 12025Oct 6, 2026
NCT07654361Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calor…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed

RecruitingPhase 33,600target71 / 12026Aug 10, 2026
NCT07662213A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 210 sites in total

RecruitingPhase 31,200target210 / 152026Oct 22, 2026
NCT07353931Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo…

✓ Contact✗ Claimed

Nearest site: Newton, Kansas, United States — 53 km away · 147 sites in total · contact listed

RecruitingPhase 3900target147 / 132026Nov 4, 2026
NCT07919678A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical fun…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 40 sites in total

RecruitingPhase 3656target40 / 22026Nov 5, 2026
NCT06190717Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total · contact listed

RecruitingNot applicable304target23 / 12024Oct 28, 2026
NCT06628908Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 76 sites in total

RecruitingPhase 31,100target76 / 12024Oct 15, 2026
NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi…

✓ Contact✗ Claimed

Nearest site: El Dorado, Kansas, United States — 85 km away · 563 sites in total · contact listed

RecruitingPhase 34,500target563 / 342025Oct 8, 2026
NCT06527222A Study of Ranolazine in ALS

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 6 sites in total · contact listed

RecruitingPhase 272target6 / 12025Nov 18, 2026
NCT07570316A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody l…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 35 sites in total · contact listed

RecruitingPhase 3230target35 / 32026Nov 3, 2026
NCT07567001A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi…

✓ Contact✗ Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total

RecruitingPhase 35,610target838 / 272026Aug 18, 2026

Filters

Clear all filters